Publications by authors named "Mathias Muth"

Claim this Profile
E
Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial.
Hans Tesch, Oliver Stoetzer, Thomas Decker, Christian M Kurbacher, Frederik Marmé, Mathias Muth

Int J Cancer· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial.
Peyman Hadji, Oliver Stoetzer, Thomas Decker, Christian M Kurbacher, Frederik Marmé, Mathias Muth

J Bone Oncol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A New Molecular Mechanism To Engineer Protean Agonism at a G Protein-Coupled Receptor.
Anna De Min, Carlo Matera, Andreas Bock, Janine Holze, Jessica Kloeckner, Mathias Muth

Mol Pharmacol· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final safety and efficacy analysis of a phase I/II trial with imatinib and vinorelbine for patients with metastatic breast cancer.
Nicolai Maass, Christian Schem, Dirk O Bauerschlag, Katharina Tiemann, Fritz W Schaefer, Mathias Muth

Oncology· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of adjuvant endocrine therapy on hormonal levels in premenopausal women with breast cancer: the ProBONE II study.
Peyman Hadji, Annette Kauka, May Ziller, Katrin Birkholz, Monika Baier, Mathias Muth

Breast Cancer Res Treat· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients.
Peter A Fasching, Sebastian M Jud, Maik Hauschild, Sherko Kümmel, Martin Schütte, Mathias Muth

BMC Cancer· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamic ligand binding dictates partial agonism at a G protein-coupled receptor.
Andreas Bock, Brian Chirinda, Fabian Krebs, Regina Messerer, Julia Bätz, Mathias Muth

Nat Chem Biol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer.
Peyman Hadji, May Ziller, Tobias Maurer, Michael Autenrieth, Mathias Muth

J Bone Oncol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity.
Johannes Antony, Kerstin Kellershohn, Marion Mohr-Andrä, Anna Kebig, Stefanie Prilla, Mathias Muth

FASEB J· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Chronic obstructive pulmonary disease].
Ulrike Holzgrabe, Mathias Muth

Med Monatsschr Pharm· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitrypanosomal activity of quaternary naphthalimide derivatives.
Mathias Muth, Verena Hoerr, Melanie Glaser, Alicia Ponte-Sucre, Heidrun Moll

Bioorg Med Chem Lett· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis, and action of oxotremorine-related hybrid-type allosteric modulators of muscarinic acetylcholine receptors.
Teresa Disingrini, Mathias Muth, Clelia Dallanoce, Elisabetta Barocelli, Simona Bertoni

J Med Chem· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Muscarinic allosteric enhancers of ligand binding: pivotal pharmacophoric elements in hexamethonio-type agents.
Mathias Muth, Matthias Sennwitz, Klaus Mohr, Ulrike Holzgrabe

J Med Chem· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic development of high affinity bis(ammonio)alkane-type allosteric enhancers of muscarinic ligand binding.
Mathias Muth, Wiebke Bender, Olaf Scharfenstein, Ulrike Holzgrabe, Edith Balatkova

J Med Chem· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis